• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Menichella Daniel L

    1/18/22 5:09:32 PM ET
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLDO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Menichella Daniel L

    (Last) (First) (Middle)
    C/O KALEIDO BIOSCIENCES
    65 HAYDEN AVENUE

    (Street)
    LEXINGTON MA 02421

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Kaleido Biosciences, Inc. [ KLDO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    01/14/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 01/14/2022 A 70,200 (2) (2) Common Stock 70,200 $0.00 70,200 D
    Restricted Stock Units (1) 01/14/2022 A 250,000 (3) (3) Common Stock 250,000 $0.00 250,000 D
    Explanation of Responses:
    1. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
    2. The restricted stock units shall vest 100% on April 30, 2022 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer.
    3. The restricted stock units shall vest on the earlier of 50% on January 14, 2023 and 50% on January 14, 2024 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer.
    Remarks:
    /s/ Daniel L. Menichella 01/18/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KLDO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KLDO

    DatePrice TargetRatingAnalyst
    1/31/2022$11.00 → $3.00Buy
    Chardan Capital
    11/12/2021$15.00 → $11.00Buy
    Chardan Capital
    11/3/2021$25.00 → $22.00Market Outperform
    JMP Securities
    10/19/2021$3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $KLDO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Kaleido Biosciences with a new price target

      Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $3.00 from $11.00 previously

      1/31/22 9:22:16 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on Kaleido Biosciences with a new price target

      Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $11.00 from $15.00 previously

      11/12/21 7:22:49 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities reiterated coverage on Kaleido Biosciences with a new price target

      JMP Securities reiterated coverage of Kaleido Biosciences with a rating of Market Outperform and set a new price target of $22.00 from $25.00 previously

      11/3/21 7:54:29 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care